IL2 and progressive multifocal leukoencephalopathy: Ethics approval and consent to participate: The patient provided written consent for the off-label use of IL-2 in the treatment of his PML and to the IRB-approved UT Southwestern Medical Center (Dallas, TX, USA) Neuroscience’s biorepository protocol allowing for specimen storage and data collection during the course of his care.